Choosing injectable PrEP for HIV prevention in Cape Town
Part of Immune system & allergy, Infections clinical trials.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must test negative for HIV at the start of the study.
- You must weigh more than 35 kilograms (77 pounds).
- You must be older than 15 years of age.
- You must live in the Cape Town study area or be there for work or school most of the time.
- You must be willing to receive an injectable medication for HIV prevention.
- You should not be allergic to any of the study products or be taking medications that interfere with them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This study tests a new injectable medication called lenacapavir to prevent HIV infection. You get to choose between different HIV prevention options, and the study will see how well the injection works for you.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
Hear when a new Sexual and Reproductive Health trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.